Roche’s Tecentriq Receives FDA Priority Review for Stage III Colon Cancer
BASEL, Switzerland, June 11, 2026 Roche has announced that the U.S. Food and Drug Administration (FDA) has granted Priority...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
BASEL, Switzerland, June 11, 2026 Roche has announced that the U.S. Food and Drug Administration (FDA) has granted Priority...
SINGAPORE, June 11, 2026 DKSH Healthcare and BridgeBio have entered into a strategic distribution and commercialization partnership aimed at...
STOCKHOLM, Sweden, June 11OSAKA, Japan and CAMBRIDGE, Massachusetts, June 11, 2026, 2026 Takeda has announced positive topline results from...
SHANGHAI, China & NEW YORK, USA – June 8, 2026 Argo Biopharma has announced positive updated Phase 2 results...
VALBY, Denmark and AMSTERDAM, Netherlands, June 3, 2026 Lundbeck and Cradle have announced a strategic partnership aimed at transforming...
REHOVOT and RAMAT-GAN, Israel, June 2, 2026 Galmed Pharmaceuticals and Tissue Dynamics have announced a significant preclinical breakthrough in...
SAN FRANCISCO, May 28, 2026 Alife Health has achieved a major milestone in reproductive medicine with the U.S. Food...
SAN DIEGO, June 1, 2026 Ansun Biopharma has announced a significant clinical development milestone after an independent Data Monitoring...
REDMOND, Wash., June 1, 2026 SystImmune has reported encouraging Phase 1 clinical data for its investigational DLL3-targeting antibody-drug conjugate...
NEW YORK, May 29, 2026 Actinium Pharmaceuticals, Inc. has announced the receipt of two patent allowances from the Canadian...
